NYSE:CANF Can-Fite BioPharma (CANF) Stock Price, News & Analysis $1.42 -0.07 (-4.70%) Closing price 11/13/2026 03:59 PM EasternExtended Trading$1.46 +0.04 (+2.82%) As of 11/13/2026 07:49 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsNews and TrendsOwnershipSEC Filings About Can-Fite BioPharma Stock (NYSE:CANF) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Can-Fite BioPharma alerts:Sign Up Key Stats Today's Range$1.42▼$1.5250-Day Range$1.42▼$2.3352-Week Range$1.42▼$12.30Volume16,816 shsAverage Volume853,540 shsMarket Capitalization$1.52 millionP/E RatioN/ADividend YieldN/APrice Target$44.00Consensus RatingModerate Buy Company Overview Can-Fite BioPharma Ltd. is an Israel-based clinical-stage biopharmaceutical company focused on developing small-molecule therapies for cancer, liver disease and inflammatory conditions. Its drug-development platform is based primarily on agonists of the A3 adenosine receptor, a biological target that the company believes may help regulate disease-related inflammatory and cancer cells while having limited effects on healthy cells. The company’s leading investigational product is namodenoson, an orally administered A3 adenosine receptor agonist being developed for metabolic dysfunction-associated steatohepatitis (MASH), formerly known as nonalcoholic steatohepatitis, and advanced hepatocellular carcinoma. Can-Fite has also developed piclidenoson, another A3 receptor agonist studied for inflammatory and autoimmune diseases, including rheumatoid arthritis and psoriasis. Founded in Israel, Can-Fite conducts its research and clinical-development activities through international programs and collaborations. The company is headquartered in Petah Tikva, Israel, and is led by founder and Chief Executive Officer Dr. Pnina Fishman. Its products remain investigational and are subject to clinical testing and regulatory review.AI Generated. May Contain Errors. Read More Can-Fite BioPharma Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks44th Percentile Overall ScoreCANF MarketRank™: 2.180648549295 of 5 starsCan-Fite BioPharma scored higher than 44% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.5 / 5Analyst RatingModerate Buy Consensus RatingCan-Fite BioPharma has received a consensus rating of Moderate Buy. The company's average rating score is 2.67, and is based on no strong buy ratings, 2 buy ratings, 1 hold rating, and no sell ratings.Upside PotentialCan-Fite BioPharma has a consensus price target of $44.00, representing about 2,998.6% upside from its current price of $1.42.Amount of Analyst CoverageCan-Fite BioPharma has only been the subject of 1 research reports in the past 90 days.Read more about Can-Fite BioPharma's stock forecast and price target. Earnings and Valuation1.3 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for Can-Fite BioPharma are expected to grow in the coming year, from ($1.25) to ($0.05) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Can-Fite BioPharma is -0.79, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Can-Fite BioPharma is -0.79, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioCan-Fite BioPharma has a P/B Ratio of 0.81. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities. Short InterestN/AShort Interest LevelN/A Short InterestThere is no current short interest data available for CANF. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldCan-Fite BioPharma does not currently pay a dividend.Dividend GrowthCan-Fite BioPharma does not have a long track record of dividend growth. News and Social Media1.6 / 5News Sentiment-0.38 News SentimentCan-Fite BioPharma has a news sentiment score of -0.38. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.57 average news sentiment score of Healthcare companies.News Coverage This WeekMarketBeat has tracked 4 news articles for Can-Fite BioPharma this week, compared to 1 article on an average week.Search Interest2 people have searched for CANF on MarketBeat in the last 30 days. Company Ownership0.3 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Can-Fite BioPharma insiders have not sold or bought any company stock.Percentage Held by Insiders0.80% of the stock of Can-Fite BioPharma is held by insiders.Percentage Held by Institutions21.00% of the stock of Can-Fite BioPharma is held by institutions.Read more about Can-Fite BioPharma's insider trading history. Receive CANF Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Can-Fite BioPharma and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. CANF Stock News HeadlinesCan-Fite's Piclidenoson Cuts Kidney Disease Marker By Up To 80% In Preclinical StudyNovember 12 at 7:53 PM | rttnews.comCan-Fite's Piclidenoson Demonstrates Up to 80% Improvement in Kidney Disease Marker in Lowe Syndrome Preclinical Study: Published in Nature Portfolio JournalNovember 12 at 7:00 AM | globenewswire.comMy public warning after 55 years of watching the marketsDr. Martin D. Weiss has publicly predicted six major American market crashes over his 55-year career, each warning issued before the crisis hit. Now the founder of Weiss Ratings, the only conflict-free rating agency in America, says he is watching a $3 trillion problem that could trigger a chain reaction across markets and banks.November 14 at 1:00 AM | Weiss Ratings (Ad)Can-Fite Highlights Long-Term Outcome From Investigational Liver Cancer Treatment StudyNovember 9, 2026 | rttnews.comCan-Fite Reports Ten-Year Survival Milestone for Advanced Liver Cancer Patient from Phase II Namodenoson StudyNovember 9, 2026 | globenewswire.comCan-Fite to Pursue Global Licensing and Strategic Partnerships at BIO-Europe 2026 Following Recent Clinical and Intellectual Property MilestonesNovember 6, 2026 | globenewswire.comCan-Fite Announces Eurasian Patent Allowance Supporting Piclidenoson Development and Commercialization in Lowe SyndromeNovember 3, 2026 | finance.yahoo.comCan-Fite Presents Final Phase 2a Data For Namodenoson In Pancreatic CancerOctober 28, 2026 | rttnews.comSee More Headlines CANF Stock Analysis - Frequently Asked Questions How have CANF shares performed this year? Can-Fite BioPharma's stock was trading at $4.00 on January 1st, 2026. Since then, CANF stock has decreased by 64.5% and is now trading at $1.42. How were Can-Fite BioPharma's earnings last quarter? Can-Fite BioPharma Ltd. (NYSE:CANF) issued its earnings results on Tuesday, November, 30th. The company reported ($38.00) EPS for the quarter, missing analysts' consensus estimates of ($18.00) by $20.00. The firm had revenue of $250 thousand for the quarter. When did Can-Fite BioPharma's stock split? Can-Fite BioPharma's stock reverse split on the morning of Monday, January 5th 2026.The 1-20 reverse split was announced on Tuesday, December 23rd 2025. The number of shares owned by shareholders was adjusted after the market closes on Sunday, January 4th 2026. An investor that had 100 shares of stock prior to the reverse split would have 5 shares after the split. How do I buy shares of Can-Fite BioPharma? Shares of CANF stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Can-Fite BioPharma own? Based on aggregate information from My MarketBeat watchlists, some other companies that Can-Fite BioPharma investors own include Advanced Micro Devices (AMD), Dynavax Technologies (DVAX), OPKO Health (OPK), Tonix Pharmaceuticals (TNXP), NIO (NIO), Sorrento Therapeutics (SRNE) and Micron Technology (MU). Company Calendar Today11/14/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Red Zone (1m+) 1-Year History Nov 25 Feb 26 May 26 Aug 26 Nov 26 CANF's financial health is in the Red zone, according to TradeSmith. CANF has been in this zone for over one month. Industry, Sector and Symbol Stock ExchangeNYSE SectorHealthcare Industry Pharmaceuticals Sub-IndustryPharmaceuticals Current SymbolNYSE:CANF CIK1536196 Webwww.canfite.com Phone972-3-924-1114Fax972-3924-9378Employees5Year FoundedN/APrice Target and Rating Average Price Target for Can-Fite BioPharma$44.00 High Price Target$80.00 Low Price Target$8.00 Potential Upside/Downside+2,998.6%Consensus RatingModerate Buy Rating Score (0-4)2.67 Research Coverage3 Analysts Profitability EPS (Trailing Twelve Months)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current Ratio2.93 Quick RatioN/A Sales & Book Value Annual Sales$405 thousand Price / Sales3.75 Cash FlowN/A Price / Cash FlowN/A Book Value$1.76 per share Price / Book0.81Miscellaneous Outstanding Shares1,070,000Free FloatN/AMarket Cap$1.52 million OptionableNot Optionable Beta1.23 7 Best Space Stocks to Own in 2026The space race is growing fast, and you don’t have to have gotten in early on SpaceX to profit. This report shows seven space stocks you can buy today that may grow as rockets, satellites, defense, space internet, and new space technology become more important.Get This Free Report This page (NYSE:CANF) was last updated on 11/13/2026 by MarketBeat.com Staff. From Our PartnersWhy I'm selling my Snapback Indicator for just $7For Black Friday, Base Camp Trading's Thomas Wood is offering lifetime access to his proprietary Snapback Indi...Base Camp Trading | SponsoredEvery Starlink dish pays this stockThere's a chip inside every Tesla and Starlink dish that Elon doesn't own. He pays royalties to use it. Now...Behind the Markets | SponsoredYour free book is about to disappearBill Poulos is giving away his 'Safe Trade Options Formula' book for free - but only for a limited time throug...Profits Run | SponsoredMy public warning after 55 years of watching the marketsDr. Martin D. Weiss has publicly predicted six major American market crashes over his 55-year career, each war...Weiss Ratings | SponsoredExecutive Order 14241 Unleashes Trump’s New DollarA landmark executive order, 14241, is reportedly set to reshape how Americans use money starting this December...Porter & Company | SponsoredURGENT: If you own a home, please review the map below.More than 1,300 red dots are scattered across the country, and 2,800 more are already on the way. Jim Rickards...Paradigm Press | SponsoredManagement just bought 2.8 million sharesManagement just backed a $100 million buyback, repurchasing 2.8 million shares at an average price of $35.26 i...Monument Traders Alliance | SponsoredLog into Keith’s $5,000 AI Signals Trading system todayA new AI system from the TradeSmith Daily team shows trades taking shape 90 minutes before they occur, with 93...TradeSmith | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Can-Fite BioPharma Ltd. Please log in to your account or sign up in order to add this asset to your watchlist. Share Can-Fite BioPharma With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
